Get the Stockscreener App
4.79
0.84%
0.04
Neuphoria Therapeutics Inc stock is traded at $4.79, with a volume of 331.97K.
It is up +0.84% in the last 24 hours and down -70.16% over the past month.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
See More
Previous Close:
$4.75
Open:
$4.65
24h Volume:
331.97K
Relative Volume:
0.22
Market Cap:
$9.01M
Revenue:
$15.66M
Net Income/Loss:
$5.83M
P/E Ratio:
-0.2005
EPS:
-23.8939
Net Cash Flow:
$466.20K
1W Performance:
+16.83%
1M Performance:
-70.16%
6M Performance:
-2.04%
1Y Performance:
+0.00%
1-Day Range:
$4.36
$4.8637
1-Week Range:
$4.15
$5.18
52-Week Range:
$2.90
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Name
Neuphoria Therapeutics Inc
Sector
Industry
Phone
781-439-5551
Address
100 SUMMIT DR, BURLINGTON
Compare NEUP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
4.79 | 11.20M | 15.66M | 5.83M | 466.20K | -23.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-28-23 | Reiterated | Maxim Group | Buy |
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
View All
Neuphoria Therapeutics Inc Stock (NEUP) Latest News
What does recent volatility data suggest for Neuphoria Therapeutics Inc.Inflation Watch & High Return Trade Guides - newser.com
Neuphoria Therapeutics Inc. (NEUP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Neuphoria Therapeutics may offer & sell common stock of up to $20 million from time to timeSEC filing - MarketScreener
Is Neuphoria Therapeutics Inc. meeting your algorithmic filter criteriaQuarterly Trade Review & Free Low Drawdown Momentum Trade Ideas - newser.com
Can Neuphoria Therapeutics Inc. stock hit analyst price targetsAnalyst Downgrade & Real-Time Price Movement Reports - Fundação Cultural do Pará
Will Neuphoria Therapeutics Inc. stock deliver shareholder value2025 Analyst Calls & Accurate Entry and Exit Point Alerts - Fundação Cultural do Pará
Neuphoria Therapeutics Inc. SEC 10-Q Report - TradingView
How to read the order book for Neuphoria Therapeutics Inc.Earnings Overview Report & Community Consensus Stock Picks - newser.com
Is Neuphoria Therapeutics Inc. showing signs of accumulation2025 Earnings Impact & Verified Swing Trading Watchlists - newser.com
What indicators show strength in Neuphoria Therapeutics Inc.Quarterly Trade Review & Free Accurate Trade Setup Notifications - newser.com
Will Neuphoria Therapeutics Inc. stock attract more institutional investors2025 Valuation Update & Long Hold Capital Preservation Tips - newser.com
What analysts say about Neuphoria Therapeutics Inc stockRSI Overbought/Oversold & Free Smart Trading Classes - earlytimes.in
Combining price and volume data for Neuphoria Therapeutics Inc.July 2025 Patterns & Safe Entry Momentum Tips - newser.com
Neuphoria Files a Preliminary Proxy Statement with Securities and Exchange Commission - MarketScreener
Is Neuphoria Therapeutics Inc. still worth holding after the dipJuly 2025 Sector Moves & Reliable Entry Point Alerts - newser.com
NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition - Stocktwits
Neuphoria Announces Receipt of Nomination Notice from Lynx1 Master - MarketScreener
Why hedge funds are buying Neuphoria Therapeutics Inc. stockMarket Weekly Review & AI Powered Buy/Sell Recommendations - newser.com
Neuphoria Shares Climb 4% After Launching Strategic Review to Enhance Shareholder Value - MSN
Neuphoria announces initiation of strategic review - MarketScreener
Neuphoria Therapeutic (NEUP) Explores Strategic Options and Faces Acquisition Interest - GuruFocus
Neuphoria stock rises after initiating strategic review By Investing.com - Investing.com Canada
Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value - Bluefield Daily Telegraph
Neuphoria (NASDAQ: NEUP) receives $5.20/share non-binding interest, engages H.C. Wainwright - Stock Titan
Lynx1 Capital Nominates Candidates to Neuphoria Therapeutics Board - MarketScreener
Can Neuphoria Therapeutics Inc. stock maintain operating marginsQuarterly Trade Review & High Accuracy Trade Alerts - newser.com
Neuphoria Therapeutics Inc expected to post a loss of $1.33 a shareEarnings Preview - TradingView
Neuphoria Therapeutics Inc Stock (NEUP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):